Novo Nordisk said Monday that it was ending a partnership with Hims & Hers Health to sell Wegovy, citing the company's promotion of "illegitamate, knockoff versions" that "put patient safety at risk."
Why it matters: The partnership termination is just the latest flashpoint between Big Pharma and GLP-1 compounding companies.
